New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
Abstract Chimeric antigen receptor (CAR) T-cell therapy represents a highly efficacious treatment modality demonstrated to enhance outcomes in patients afflicted with malignancies, particularly those enduring relapsed or refractory hematological malignancies. However, the escalating adoption of CAR...
Saved in:
| Main Authors: | Yuanyuan Yang, Hongwei Peng, Jianxiang Wang, Fei Li |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Experimental Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40164-024-00573-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology
by: Alina Ershova, et al.
Published: (2025-07-01) -
Efficacy and safety of CD19 combined with CD22 or CD20 chimeric antigen receptor T-cell therapy for hematological malignancies
by: Xiaoshuang Yuan, et al.
Published: (2025-05-01) -
CAR-T: from bench to bedside
by: M. О. Popova, et al.
Published: (2024-09-01) -
Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells
by: Yang Liu, et al.
Published: (2025-01-01) -
Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases
by: Alejandrina Hernández-López, et al.
Published: (2025-01-01)